Abstract

Bir lökotrien reseptör antagonisti olan montelukast çocukluk çağı astım tedavisinde sıklıkla kullanılan bir ajandır. İlacın çeşitli
nöropsikiyatrik yan etkileri giderek artan bir şekilde rapor edilmektedir. Bu olgu sunumunda, daha öncesinde genetik yatkınlığı
ve psikolojik sorunu olmayan, montelukast kullanımı sonrası depresyon ve intihar düşüncesi/davranışı sergileyen, ilaç
kesilmesi ile yakınmaları tamamen kaybolan bir olguyu rapor ediyoruz.

Keywords: Çocuk, İntihar, Lökotrien reseptör antagonistleri, Montelukast, Nöropsikiyatri, Yan etki

References

  1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31: 143-78.
  2. Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribinginformation. jsp accessed 17/09/10.
  3. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706.
  4. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Engl J Med 1998;339:147-52.
  5. Leukotriene inhibitors: Montelukast (marketed as Singulair), zafi rlukast (marketed as Accolate), and zileuton (marketed as Zyfl o and Zyfl o CR). Healthcare Professional Sheet, Washington (DC): US Food and Drug Administration; 2009. Available from: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s0 51_020830s052_021409s028lbl.pdf.
  6. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:568-79.
  7. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
  8. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6.
  9. Skillman KL, Stumpf JL. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011;31:524
  10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.

Copyright and license

Copyright © 2014 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Çelmeli F, Çelmeli G, Sürer Adanır A, Türkkahraman D. Montelukast Kullanımı Sonrası İnti̇har Düşüncesi̇ ve Davranışı Gösteren Olgu. Turk J Pediatr Dis [Internet]. 2014 Apr. 1 [cited 2025 Jul. 8];8(4):212-4. Available from: https://turkjpediatrdis.org/article/view/1145